This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial
Truly a LANDMARK trial. The investigators went to prove that lanthanum is superior to calcium for phosphate binding. What they found will surprise no one.
Join us for the first edition of the #NephTrials chat. Let’s take a deep dive into pragmatic trials, and take a specific example - the Phosphate trial, to anchor the discussion.
First chat of 2019 - showcasing again the honest brokers of nephrology trials with another negative trial. Also note we will be having a NephJC Asia chat starting this week!